EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RAD21 promotes oncogenesis and lethal progression of prostate cancer

Xiaofeng A Su iD, Konrad H Stopsack iD, Daniel R Schmidt, Duanduan Ma, Zhe Li, Paul A Scheet, Kathryn L Penney iD, Tamara L Lotan, Wassim Abida, Elise G DeArment, Kate Lu, Thomas Janas iD und 6 weitere

Proceedings of the National Academy of Sciences · 03.09.2024 · 121 (36)

DOI: 10.1073/pnas.2405543121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 27.08.2024. Verfasst von Xiaofeng A Su und 17 weiteren Autor:innen. Beteiligte Einrichtung: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139. Hauptthemen laut MEDLINE: Prostatic Neoplasms, DNA-Binding Proteins, Cell Cycle Proteins, Aneuploidy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paul F. Glenn Center for Biology of Aging Research, Prostate Cancer Foundation (PCF), HHMI (HHMI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this study, we assessed in patients which genes on chromosome 8q, one of the most frequently gained chromosome arms in prostate tumors, were most strongly associated with long-term risk of cancer progression to metastases and death from prostate cancer (lethal disease) in 403 patients and found the strongest candidate was cohesin subunit gene, RAD21 , with an odds ratio of 3.7 (95% CI 1.8, 7.6) comparing the highest vs. lowest tertiles of mRNA expression and adjusting for overall aneuploidy burden and Gleason score, both strong prognostic factors in primary prostate cancer. Studying prostate cancer driven by the TMPRSS2-ERG oncogenic fusion, found in about half of all prostate tumors, we found that increased RAD21 alleviated toxic oncogenic stress and DNA damage caused by oncogene expression. Data from both organoids and patients indicate that increased RAD21 thereby enables aggressive tumors to sustain tumor proliferation, and more broadly suggests one path through which tumors benefit from aneuploidy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDNA-Binding ProteinsCell Cycle ProteinsAneuploidyCarcinogenesisDisease ProgressionHumansMaleNuclear ProteinsOncogene Proteins, FusionChromosomes, Human, Pair 8Gene Expression Regulation, NeoplasticDNA Damage

Stichwörter der Autor:innen

DNA damageRAD21clinical outcomesorganoidprostate cancer

Substanzen

RAD21 protein, humanDNA-Binding ProteinsCell Cycle ProteinsNuclear ProteinsOncogene Proteins, FusionTMPRSS2-ERG fusion protein, human

Autor:innen und Institutionen

  • David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817.
  • Henry M Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD 20817.
  • Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20817.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115.

ORCID-Profile: Xiaofeng A Su, Konrad H Stopsack, Kathryn L Penney, Thomas Janas, Sofia Hu, Matthew G Vander Heiden

Förderung

  • Paul F. Glenn Center for Biology of Aging Research
  • Prostate Cancer Foundation (PCF)
  • HHMI (HHMI)
  • MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT
  • Bridge Project, Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center
  • HHS | NIH | National Cancer Institute (NCI)
  • PEER Award by the Zhu Center for Global Cancer Prevention
  • Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund)

Zitieren

APA

Su, X. A., Stopsack, K. H., Schmidt, D. R., Ma, D., Li, Z., Scheet, P. A., Penney, K. L., Lotan, T. L., Abida, W., DeArment, E. G., Lu, K., Janas, T., Hu, S., Vander Heiden, M. G., Loda, M., Boselli, M., Amon, A., & Mucci, L. A. (2024). RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proceedings of the National Academy of Sciences, 121(36). https://doi.org/10.1073/pnas.2405543121

Vancouver

Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, et al. RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proceedings of the National Academy of Sciences. 2024;121(36). doi:10.1073/pnas.2405543121

BibTeX
@article{Su2024,
  author = {Su, Xiaofeng A and Stopsack, Konrad H and Schmidt, Daniel R and Ma, Duanduan and Li, Zhe and Scheet, Paul A and Penney, Kathryn L and Lotan, Tamara L and Abida, Wassim and DeArment, Elise G and Lu, Kate and Janas, Thomas and Hu, Sofia and Vander Heiden, Matthew G and Loda, Massimo and Boselli, Monica and Amon, Angelika and Mucci, Lorelei A},
  title = {RAD21 promotes oncogenesis and lethal progression of prostate cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {36},
  doi = {10.1073/pnas.2405543121}
}
Kostenlos starten →